Cryocell International Stock Performance
| CCEL Stock | USD 7.79 0.17 2.23% |
CryoCell International has a performance score of 4 on a scale of 0 to 100. The firm shows a Beta (market volatility) of -0.0374, which signifies not very significant fluctuations relative to the market. As returns on the market increase, returns on owning CryoCell International are expected to decrease at a much lower rate. During the bear market, CryoCell International is likely to outperform the market. CryoCell International right now shows a risk of 3.23%. Please confirm CryoCell International skewness, and the relationship between the potential upside and rate of daily change , to decide if CryoCell International will be following its price patterns.
Risk-Adjusted Performance
4 of 100
Weak | Strong |
Insignificant
Compared to the overall equity markets, risk-adjusted returns on investments in CryoCell International are ranked lower than 4 (%) of all global equities and portfolios over the last 90 days. Despite quite unsteady technical and fundamental indicators, CryoCell International may actually be approaching a critical reversion point that can send shares even higher in March 2025. ...more
Actual Historical Performance (%)
One Day Return 2.23 | Five Day Return 3.65 | Year To Date Return 5.62 | Ten Year Return 246.22 | All Time Return 55.8 |
Forward Dividend Yield 0.1312 | Payout Ratio | Forward Dividend Rate 1 | Dividend Date 2024-11-29 | Ex Dividend Date 2025-02-14 |
1 | Disposition of 10000 shares by Oleg Mikulinsky of CryoCell International at 4.34 subject to Rule 16b-3 | 11/12/2024 |
| CryoCell International dividend paid on 29th of November 2024 | 11/29/2024 |
2 | Acquisition by Berger Harold D. of 7500 shares of CryoCell International at 2.4 subject to Rule 16b-3 | 12/20/2024 |
3 | Acquisition by David Portnoy of 50000 shares of CryoCell International at 4.3 subject to Rule 16b-3 | 01/08/2025 |
4 | Acquisition by David Portnoy of 24447 shares of CryoCell International at 13.5 subject to Rule 16b-3 | 01/17/2025 |
5 | Acquisition by Jill Taymans of 10000 shares of CryoCell International at 7.35 subject to Rule 16b-3 | 01/21/2025 |
6 | Cryo-Cells Double Announcement Cash Reward for Shareholders but MA Plans Freeze - StockTitan | 01/29/2025 |
| Begin Period Cash Flow | 1.7 M |
CryoCell |
CryoCell International Relative Risk vs. Return Landscape
If you would invest 716.00 in CryoCell International on November 2, 2024 and sell it today you would earn a total of 63.00 from holding CryoCell International or generate 8.8% return on investment over 90 days. CryoCell International is currently generating 0.1934% in daily expected returns and assumes 3.229% risk (volatility on return distribution) over the 90 days horizon. In different words, 28% of stocks are less volatile than CryoCell, and 97% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
CryoCell International Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for CryoCell International's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as CryoCell International, and traders can use it to determine the average amount a CryoCell International's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0599
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | CCEL | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 3.23 actual daily | 28 72% of assets are more volatile |
Expected Return
| 0.19 actual daily | 3 97% of assets have higher returns |
Risk-Adjusted Return
| 0.06 actual daily | 4 96% of assets perform better |
Based on monthly moving average CryoCell International is performing at about 4% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of CryoCell International by adding it to a well-diversified portfolio.
CryoCell International Fundamentals Growth
CryoCell Stock prices reflect investors' perceptions of the future prospects and financial health of CryoCell International, and CryoCell International fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on CryoCell Stock performance.
| Return On Equity | 1.29 | ||||
| Return On Asset | -0.0013 | ||||
| Profit Margin | (0.28) % | ||||
| Operating Margin | 0.17 % | ||||
| Current Valuation | 71.04 M | ||||
| Shares Outstanding | 8.06 M | ||||
| Price To Earning | 10.76 X | ||||
| Price To Book | 9.72 X | ||||
| Price To Sales | 1.97 X | ||||
| Revenue | 31.34 M | ||||
| Gross Profit | 19.71 M | ||||
| EBITDA | (10.42 M) | ||||
| Net Income | (9.52 M) | ||||
| Cash And Equivalents | 2.96 M | ||||
| Cash Per Share | 0.35 X | ||||
| Total Debt | 10.9 M | ||||
| Debt To Equity | 0.26 % | ||||
| Current Ratio | 0.47 X | ||||
| Book Value Per Share | (1.19) X | ||||
| Cash Flow From Operations | 8.92 M | ||||
| Earnings Per Share | (1.07) X | ||||
| Market Capitalization | 62.8 M | ||||
| Total Asset | 61.22 M | ||||
| Retained Earnings | (31.16 M) | ||||
| Working Capital | (11.41 M) | ||||
| Current Asset | 6.08 M | ||||
| Current Liabilities | 2.82 M | ||||
About CryoCell International Performance
By examining CryoCell International's fundamental ratios, stakeholders can obtain critical insights into CryoCell International's financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that CryoCell International is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 38.23 | 36.32 | |
| Return On Tangible Assets | (0.15) | (0.14) | |
| Return On Capital Employed | (0.27) | (0.26) | |
| Return On Assets | (0.14) | (0.15) | |
| Return On Equity | 0.99 | 1.04 |
Things to note about CryoCell International performance evaluation
Checking the ongoing alerts about CryoCell International for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for CryoCell International help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| CryoCell International had very high historical volatility over the last 90 days | |
| CryoCell International currently holds 10.9 M in liabilities with Debt to Equity (D/E) ratio of 0.26, which may suggest the company is not taking enough advantage from borrowing. CryoCell International has a current ratio of 0.46, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Note, when we think about CryoCell International's use of debt, we should always consider it together with its cash and equity. | |
| The entity reported the previous year's revenue of 31.34 M. Net Loss for the year was (9.52 M) with profit before overhead, payroll, taxes, and interest of 19.71 M. | |
| CryoCell International has a poor financial position based on the latest SEC disclosures | |
| About 48.0% of CryoCell International shares are held by company insiders | |
| Latest headline from news.google.com: Cryo-Cells Double Announcement Cash Reward for Shareholders but MA Plans Freeze - StockTitan |
- Analyzing CryoCell International's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether CryoCell International's stock is overvalued or undervalued compared to its peers.
- Examining CryoCell International's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating CryoCell International's management team can have a significant impact on its success or failure. Reviewing the track record and experience of CryoCell International's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of CryoCell International's stock. These opinions can provide insight into CryoCell International's potential for growth and whether the stock is currently undervalued or overvalued.
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in CryoCell International. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income. For more information on how to buy CryoCell Stock please use our How to buy in CryoCell Stock guide.You can also try the Investing Opportunities module to build portfolios using our predefined set of ideas and optimize them against your investing preferences.
Is Health Care Providers & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of CryoCell International. If investors know CryoCell will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about CryoCell International listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.625 | Earnings Share (1.07) | Revenue Per Share | Quarterly Revenue Growth 0.025 | Return On Assets |
The market value of CryoCell International is measured differently than its book value, which is the value of CryoCell that is recorded on the company's balance sheet. Investors also form their own opinion of CryoCell International's value that differs from its market value or its book value, called intrinsic value, which is CryoCell International's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because CryoCell International's market value can be influenced by many factors that don't directly affect CryoCell International's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between CryoCell International's value and its price as these two are different measures arrived at by different means. Investors typically determine if CryoCell International is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, CryoCell International's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.